PROBALAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Probalan, and what generic alternatives are available?
Probalan is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in PROBALAN is probenecid. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the probenecid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Probalan
A generic version of PROBALAN was approved as probenecid by WATSON LABS TEVA on March 29th, 1983.
Summary for PROBALAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 5 |
Patent Applications: | 2,614 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROBALAN at DailyMed |
Recent Clinical Trials for PROBALAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Washington State University | Early Phase 1 |
National Institutes of Health (NIH) | Early Phase 1 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for PROBALAN
US Patents and Regulatory Information for PROBALAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lannett | PROBALAN | probenecid | TABLET;ORAL | 080966-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |